Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Duerr

Interventional Cardiology Boise, ID Medical Doctor

NPI 1588611263 CMS profile 117213

300 E Jefferson St, Suite 101, Boise, ID 83712

Open in the dashboard

General payments

$10,871

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Duerr of Boise, ID is reported in the CMS Open Payments database as having received $10,871 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,971 102
2024 General $3,536 85
2023 General $1,239 51
2022 General $935 25
2021 General $821 30
2020 General $505 27
2019 General $863 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Duerr
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Robert Duerr were reported at $2,971. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Robert Duerr Interventional Cardiology median Middle half National median
2019 $863 $1,097 $329–$3,048 $163
2020 $505 $473 $161–$1,480 $114
2021 $821 $677 $233–$1,827 $132
2022 $935 $978 $333–$2,724 $149
2023 $1,239 $1,136 $382–$2,986 $160
2024 $3,536 $1,181 $395–$3,326 $164
2025 $2,971 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $4,831 139 payments
  2. Boston Scientific Corporation $3,169 159 payments
  3. Abbott Laboratories $2,201 30 payments
  4. Medtronic, Inc. $450 12 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $67 4 payments
  6. AstraZeneca Pharmaceuticals LP $53 2 payments
  7. Medtronic Vascular, Inc. $36 2 payments
  8. iRhythm Technologies, Inc. $24 1 payment
  9. Shockwave Medical, Inc $21 1 payment
  10. Abiomed $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,357 339 payments
  2. Travel and Lodging $2,513 12 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $896 42 payments
  2. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $844 27 payments
  3. EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (THV) $607 29 payments
  4. PASCAL $603 4 payments
  5. VersaCross Steerable Access Solution $508 25 payments
  6. WATCHMAN FLX $468 24 payments
  7. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $396 11 payments
  8. Edwards SAPIEN XT Transcatheter Heart Valve $372 19 payments
  9. Mitra Clip system $316 7 payments
  10. COREVALVE EVOLUT R $288 7 payments
  11. Other $2,553 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

185

Median for Interventional Cardiology: 2,236

Drug cost

$1,555

Median for Interventional Cardiology: $380,412

Branded share of claims

30.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 56 $609
Atorvastatin Calcium Generic 56 $381
Metoprolol Succinate Generic 19 $202
Warfarin Sodium Generic 15 $156
Metoprolol Tartrate Generic 23 $111
Mupirocin Generic 16 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$69,375

Medicare's payments for the services billed

Medicare patients

981

Average age 76

Services billed

1,591

481 women, 500 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Atrial fibrillation 40%
Ischemic heart disease 37%
Heart failure 34%
Chronic kidney disease 33%
Diabetes 32%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record